Showing 3091-3100 of 3196 results for "".
- Daniel Siegel, MD Appointed to Board of Directors for Caliber Imaging & Diagnosticshttps://practicaldermatology.com/news/20140113-daniel_siegel_md_appointed_to_cabilber_imaging__diagnostics_board_of_directors/2459374/Caliber Imaging & Diagnostics, formerly Lucid, Inc., appointed Daniel Mark Siegel, MD to its Board of Directors, effective immediately. This increases the number of Board members to eight. Dr. Siegel is Clinical Professor of Dermatology at SUNY Downstate Medical Center (State Univ
- Suneva Medical Announces 12-Month Safety Results From Artefill® Acne Scar Studyhttps://practicaldermatology.com/news/20140107-suneva_medical_announces_12-month_safety_results_from_artefill_acne_scar_study/2459379/Suneva Medical Inc. announced the 12-month follow-up data from its randomized, double-blinded, multi-center, Pivotal acne scar investigational study evaluating the safety and efficacy of ArteFillâ, a dermal filler, to treat acne scars.
- Promius Pharma®, LLC Introduces Isotretinoin Indigent Patient Assistance Programhttps://practicaldermatology.com/news/20140106-promius_pharma_llc_introduces_isotretinoin_indigent_patient_assistance_program/2459381/Promius Pharma is introducing a Promius Promise Patient Assistance Program for eligible patients who are uninsured, or whose insurance company does not provide coverage of isotretinoin and who otherwise meet program eligibility requirements. This program, which is integrated into the Promius Promise
- FDA Files sBLA for Xolair in Patients with Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20131011-genentech_files_sbla_for_xoliar_in_patients_with_cronic_idiopathic_urticaria/2459437/The FDA accepted and filed Genentech's supplemental Biologics License Application (sBLA) for subcutaneous use of Xolair® (omalizumab) in people with Chronic Idiopathic Urticaria (CIU) who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses. The filing was primarily
- KYTHERA Announces Positive ATX-101 Top Line Phase III Trial Resultshttps://practicaldermatology.com/news/20130925-kythera_announces_positive_atx-101_top_line_phase_iii_trial_results/2459452/KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints. These two pivotal Phase III trials were conducted in the U.S. and Canada to compare the efficacy and safety of a 2 mg/cm2 dose of ATX-101 v
- Nucletron Introduces Esteya Electronic Brachytherapy for Treating Skin Cancerhttps://practicaldermatology.com/news/20130923-nucletron_introduces_esteya_electronic_brachytherapy_for_treating_skin_cancer/2459456/Nucletron, an Elekta company, recently launched Esteya, a new approach for treating patients with skin cancer. Esteya electronic brachytherapy mimics proven high dose rate (HDR) brachytherapy by bringing a small X-ray source very close to the cancerous site, enabling the local a
- Merz North America Appoints New Chief Financial Officerhttps://practicaldermatology.com/news/20130807-merz_north_america_appoints_new_chief_financial_officer/2459482/Merz North America has appointed John Donofrio as Chief Financial Officer and Head of Business Development - North America. In this role, Donofrio will be primarily accountable for financial performance, cost management, and strategic business planning and analysis for the Finance organization in No
- Phase III Data Show Galderma's Topical Redness Reducer is Effective, Safehttps://practicaldermatology.com/news/20130625-phase_iii_data_show_galdermas_topical_redness_reducer_is_effective_safe/2459511/Topical brimonidine tartrate gel 0.5% is safe and effective for the management of erythema of rosacea, with benefit evidence as early as 30 minutes after application, new data show. (JDD, 12(6):650-656) Data from two identically designed randomized, double-blind, vehicle controlled phase III trials
- Artefill Shows Efficacy for Atrophic Acne Scars: Datahttps://practicaldermatology.com/news/20130624-artefill_shows_efficacy_for_atrophic_acne_scars_data/2459513/Recently reported data suggest that ArteFill dermal filler is an effective option to treat atrophic acne scars. Suneva Medical shared promising six-month results from its randomized, double-blinded, multi-center, controlled study that evaluated the
- Jurlique Product Supports the Underservedhttps://practicaldermatology.com/news/20130607-jurlique_product_supports_the_underserved/2459521/The Jurlique Ideas of Beauty Fund by Jurlique and Chrysalis supports the empowerment of women to lead better lives. Through the fund, Jurlique donates to organizations around the world committed to helping women. Proceeds from every